Clinical Characteristics and Prognostic Factors of Patients with Severe Pulmonary Hypertension

Background and Objectives:The aim of this study was to investigate the clinical characteristics and predictors of the prognosis for patients with severe pulmonary hypertension (PHT). Subjects and Methods:A total of 169 patients with severe PHT (systolic pulmonary arterial pressure ≥70 mmHg by Doppler echocardiogram) were divided into two groups according to the mortality during 2.8±2.2 year clinical follow-up period: group I (moribund group, 34 patients, 60.0±15.7 years, 18 males) and group II (survived group, 135 patients, 57.2±16.9 years, 65 males). The clinical, electrocardiographic and echocardiographic variables were analyzed. Results:The three most common etiologies were valvular heart disease (VHD)(n=55: 32.9%), pulmonary thromboembolism (n= 29: 17.2%) and ischemic cardiomyopathy (n=17: 10.1%). The common presenting clinical symptoms were dyspnea on exertion, leg edema, cough and chest discomfort. Among the variables, the WHO functional classification at presentation [95% confidence interval (CI) 2.065-221.168, p=0.010], atrial fibrillation (AF)(95% CI 1.01410.161, p=0.041) and the left ventricular ejection fraction (LVEF)(95% CI 1.011-4.545, p=0.047) were significantly associated with the prognosis. Conclusion:VHD was the most common cause of severe PHT. The WHO functional classification at presentation, the presence of AF and low LVEF at presentation were the significant predictors of mortality for patients with severe PHT. (Korean Circulation J 2007;37:265-270)

[1]  R. Kachel,et al.  Thrombembolische pulmonale Hypertonie , 2007, Pneumologie.

[2]  K. Shields,et al.  Sildenafil citrate for the treatment of pulmonary hypertension. , 2006, Drugs of today.

[3]  M. Gomberg-Maitland,et al.  Endothelin receptor antagonism in pulmonary arterial hypertension – a role for selective ETA inhibition? , 2006, Current medical research and opinion.

[4]  C. Ricachinevsky,et al.  Treatment of pulmonary arterial hypertension. , 2006, Jornal de pediatria.

[5]  Hyun-Joong Kim,et al.  Impact of Pulmonary Hypertension on the Regional Right Ventricular Strain , 2006 .

[6]  E. Fadel,et al.  Pulmonary hypertension after pulmonary emboli: an underrecognized condition , 2006, Canadian Medical Association Journal.

[7]  M. Pfeffer,et al.  Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. , 2006, Journal of the American College of Cardiology.

[8]  A. Torbicki,et al.  Pulmonary arterial hypertension: evaluation of the newly diagnosed patient. , 2005, Seminars in respiratory and critical care medicine.

[9]  M. Chakinala.  Changing the prognosis of pulmonary arterial hypertension: impact of medical therapy. , 2005, Seminars in respiratory and critical care medicine.

[10]  R. Barst,et al.  Erratum: "Survival with first-line bosentan in patients with primary pulmonary hypertension" (European Respiratory Journal (2005) vol. 25 (244-249)) , 2005 .

[11]  R. Barst,et al.  Survival with first-line bosentan in patients with primary pulmonary hypertension , 2005, European Respiratory Journal.

[12]  H. Palevsky,et al.  Surrogate end points for pulmonary arterial hypertension. , 2004, American heart journal.

[13]  R. Speich,et al.  Clinical classification of pulmonary hypertension. , 2004, Journal of the American College of Cardiology.

[14]  A. Waxman,et al.  Pulmonary hypertension: Work in progress , 2003, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

[15]  J. Sims.  What's new in pulmonary artery hypertension. , 2003, Dimensions of critical care nursing : DCCN.

[16]  Jae Woo Lee,et al.  A Clinical Review of Primary Pulmonary Hypertension , 2003 .

[17]  G. Funk,et al.  Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension. , 2003, Chest.

[18]  L. Rubin.  Therapy of pulmonary hypertension: the evolution from vasodilators to antiproliferative agents. , 2002, American journal of respiratory and critical care medicine.

[19]  M. Humbert,et al.  Risk factors for pulmonary arterial hypertension. , 2001, Clinics in chest medicine.

[20]  H. Gwon,et al.  Role of echocardiography as a screening test in patients with suspected pulmonary embolism , 2001 .

[21]  K. Peterson,et al.  Cardiac Catheterization: Methods, Diagnosis, and Therapy , 1996 .

[22]  R. Gómez de la Torre,et al.  [Thromboembolic pulmonary hypertension]. , 1995, Anales de medicina interna.

[23]  P. Yock,et al.  Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. , 1984, Circulation.

[24]  W. Auger,et al.  Chronic thromboembolic pulmonary hypertension. , 2009, Seminars in respiratory and critical care medicine.

[25]  James B. Seward,et al.  The echo manual , 2006 .

[26]  V. R. Figueroa,et al.  Iloprost en la hipertensión pulmonar tromboembólica crónica , 2004 .

[27]  V. Roig Figueroa,et al.  Iloprost for chronic thromboembolic pulmonary hypertension. , 2004, Archivos de bronconeumologia.

[28]  T. Evans,et al.  Pathophysiology and pharmacological treatment of pulmonary hypertension in acute respiratory distress syndrome , 2003, European Respiratory Journal.

[29]  J. Higenbottam.  Recommendations on the management of pulmonary hypertension in clinical practice. , 2001, Heart.

[30]  Basic dysrhythmias. , 1989, Critical care nurse.